2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.780
-0.050 (-1.31%)
Jul 4, 2025, 4:51 PM CET
575.00%
Market Cap 94.64M
Revenue (ttm) 1.98M
Net Income (ttm) -26.35M
Shares Out 25.10M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend 0.08 (2.22%)
Ex-Dividend Date Jun 27, 2025
Volume 240,524
Average Volume 479,008
Open 3.890
Previous Close 3.830
Day's Range 3.680 - 4.130
52-Week Range 0.330 - 5.520
Beta 1.53
RSI 59.06
Earnings Date Aug 21, 2025

About 2cureX AB

2cureX AB (publ) operates as a medtech company in Europe. The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. The company was incorporated in 2006 and is based in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements

News

There is no news available yet.